6 Dividend Stocks Ready To Benefit From 2026's Rate-Shift Economy

Let's get our 2026 dividend shopping finished ahead of time, shall we?

Forbes • Dec 4, 2025

BMEZ: NAV Decline Continues And Underperforms Peers

BlackRock Health Sciences Term Trust continues to struggle with unsustainable distributions and rapid NAV decline, prompting a maintained Sell rating. BMEZ's high 8.4% yield is not supported by net investment income, leading to persistent NAV erosion and reliance on return of capital. Despite broad healthcare exposure and option strategies, BMEZ underperforms peers like THQ and BME in total return and capital preservation.

Seeking Alpha • Nov 28, 2025

Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

NEW YORK--(BUSINESS WIRE)--Today, BlackRock Resources & Commodities Strategy Trust (NYSE: BCX), BlackRock Enhanced Equity Dividend Trust (NYSE: BDJ), BlackRock Energy and Resources Trust (NYSE: BGR), BlackRock Enhanced International Dividend Trust (NYSE: BGY), BlackRock Health Sciences Trust (NYSE: BME), BlackRock Health Sciences Term Trust (NYSE: BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE: BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE: BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE: CII), BlackRock Science and Technology Trust (NYSE: BST), BlackRock Science and Technology Term Trust (NYSE: BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE: BTX), BlackRock Capital Allocation Term Trust (NYSE: BCAT), and BlackRock ESG Capital Allocation Term Trust (NYSE: ECAT) (collectively, the “Funds”) paid the following distributions per share

Business Wire • Nov 28, 2025

A Dividend Cut Just Created A 9.2% Monthly Dividend Bargain

Most Wall Street “suits” are allergic to dividend cuts. These spreadsheet jockeys sooooo lack imagination.

Forbes • Sep 18, 2025

BlackRock Announces Update to BMEZ, BSTZ, and BTX Managed Distribution Plans

NEW YORK--(BUSINESS WIRE)---- $BMEZ--The Board of Trustees (the "Board") of BlackRock Health Sciences Term Trust (BMEZ), BlackRock Science and Technology Term Trust (BSTZ), and BlackRock Technology and Private Equity Term Trust (BTX) (the “Funds”) approved updates to each Fund's managed distribution plan that will take effect with the October 2025 distribution. The Funds will change from a floating rate distribution to a level rate distribution at the stated monthly rates provided below. These changes se.

Business Wire • Sep 11, 2025

Revisiting BMEZ: Why The Widening Discount Warrants A 'Hold' Rating

BMEZ's discount to NAV has widened back to nearly 10%, making it less of an urgent sell but not yet a buy. The fund's 13.74% distribution rate is appealing, but it is entirely return of capital, raising sustainability concerns. Significant private investments and a high distribution rate may further pressure the discount, especially if distributions are cut.

Seeking Alpha • Sep 8, 2025

5 Closed-End Fund Buys In The Month Of July 2025

With the month of July closing out, we are once again seeing the broader equity markets pushing to new all-time highs. As we enter into new all-time highs, we appear to be looking quite stretched on valuations, and CEF discounts have been narrowing.

Seeking Alpha • Aug 14, 2025

BMEZ: This Healthcare Fund Is Paying Out More Than It Earns

BlackRock Health Sciences Term Trust (BMEZ) exposes investors to life science companies but the performance has been flawed since inception. The fund writes options against its holdings, which helps amplify income levels but makes it difficult for the fund to participate in capital appreciation. BMEZ offers a high dividend yield of 14.2% but the fund is paying out more than it actually earns.

Seeking Alpha • Aug 2, 2025

Why I Moved On From BMEZ Despite A 14.2% Yield (Rating Downgrade)

BlackRock Health Sciences Term Trust's discount to NAV has narrowed sharply, eroding the original deep-value thesis and making the risk/reward profile less attractive. BlackRock's tender offer and increased distributions successfully closed the discount, but future activist pressure is now limited due to Saba's standstill agreement. The fund's high 14% yield is appealing but unsustainable, as it relies on return of capital rather than underlying earnings, especially in biotech.

Seeking Alpha • May 19, 2025

7 Closed-End Fund Buys (And 4 Sells) In The Month Of April 2025

April's market volatility, driven by tariffs and led by tech sector declines, created opportunities to deploy cash. However, it was an opportunity to reposition my portfolio as well, with 2 swap trades to de-risk my portfolio. There were 2 corporate actions in the last month that also saw two more positions removed from my CEF portfolio, but overall, I was a net buyer for the month.

Seeking Alpha • May 14, 2025